Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Exclusion Criteria

• •Homozygous familial hypercholesterolemia
• •Low-Density Lipoprotein (LDL) or plasma apheresis within 12 months prior to randomization
• •New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30%
• •Uncontrolled cardiac arrhythmia
• •Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
• •Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (HbA1c \> 8.5%)
• •Uncontrolled hypertension